Skip to main content

Table 1 Characteristics of the patients at baseline and according to the primary end point occurrence

From: Clinical outcomes after primary prevention defibrillator implantation are better predicted when the left ventricular ejection fraction is assessed by cardiovascular magnetic resonance

 

N = 173

Death or ADT

p

p for survival

Yes (n = 66)

No (n = 107)

Follow-up, months (mean ± SD)

50,3 ± 30,3

52,5 ± 28,7

46,7 ± 32,7

0,223

 

Age, years (mean ± SD)

59 ± 12

60 ± 13

58 ± 11

0,554

(≥ vs < 58) 0,979

Male, n (%)

149 (86)

62 (94)

87 (81)

0,023

0,206

BMI, kg/m2 (mean ± SD)

27.2 ± 5

27.9 ± 4

26.9 ± 5

0.476

(≥ vs < 27) 0.730

ICM, n (%)

120 (69)

54 (82)

66 (62)

0,006

0,046

Revascularization, n(%)

 PCI

74 (62)

33 (59)

41 (64)

0.132

0.026

 CABG

14 (12)

10 (18)

4 (6)

 None

32 (27)

13 (23)

19 (30)

Diabete mellitus, n (%)

40 (23)

14 (21)

26 (24)

0,712

0,819

Hypertension, n (%)

49 (28)

24 (36)

25 (23)

0,082

0,046

Smokers, n (%)

64 (37)

28 (42)

36 (34)

0,260

0,918

COPD (Gold ≥2), n (%)

18 (10)

10 (14)

8 (8)

0.203

0.316

Cancer, n (%)

4 (2.3)

2 (3)

2 (2)

1

0.299

AF, n (%)

35 (20)

20 (30)

15 (14)

0,012

0,196

NYHA class, n (%)

 I

28 (16)

9 (14)

19 (18)

0,270

II vs I: 0,508

 II

99 (57)

35 (53)

64 (60)

III vs I: 0,079

 III

46 (27)

22 (33)

24 (22)

III vs I + II: 0,054

Heart rate, ppm (mean ± SD)

69 ± 16

66 ± 13

71 ± 18

0,108

0,354

QRS duration, ms (mean ± SD)

124 ± 33

121 ± 32

125 ± 34

0,413

0,384

eGFR, ml/min (mean ± SD)

67.4 ± 20.3

59.5 ± 17.7

67.4 ± 19.9

0.008

(≥ vs < 60) 0.932

CKD 3b, n (%)

25 (15)

15 (22)

10 (10)

0.03

0.316

Betablockers, n (%)

163 (94)

64 (97)

99 (93)

0,321

0,270

ARB or ACEI, n (%)

163 (94)

62 (94)

101 (94)

1000

0,661

Diuretics, n (%)

124 (72)

47 (71)

77 (72)

1000

0,939

MRA, n (%)

105 (61)

41 (62)

64 (60)

0,873

0,556

Resynchronization therapy, n (%)

56 (32)

21 (32)

35 (33)

1000

0,978

MAGGIC Score (mean ± SD)

20 ± 6

22 ± 7

19 ± 5

0.040

(≥ vs < 19) 0.105

Sodium, mmol/l (mean ± SD)

138 ± 3

137 ± 3

138 ± 3

0.071

(≥ vs < 138) 0.920

BNP, pg/ml (mean ± SD)

625 ± 622

674 ± 511

592 ± 689

0.449

(≥ vs < 400) 0.462

Hematocrit, % (mean ± SD)

40 ± 19

39 ± 4

41 ± 4

0.042

(≥ vs < 41) 0.035

2D echo-LVEF, % (mean ± SD)

27,5 ± 6,3

27 ± 6

28 ± 7

0,500

0,256

2DEcho-LVEF< 26, n (%)

63 (36)

30 (46)

33 (33)

0,141

0,052

CMR-LVEF, % (mean ± SD)

23,4 ± 6,7

22 ± 7

24 ± 7

0,087

0,010

CMR-LVEF< 22, n (%)

60 (35)

28 (42)

32 (30)

0,102

0,005

LGE, n(%)

133 (77)

58 (87)

75 (71)

0,017

0,058

LGE and CMR-LVEF< 22, n(%)

44 (25)

26 (39)

18 (18)

0,002

< 0,001

LGE and 2D echo-LVEF< 26, n(%)

50 (29)

28 (42)

22 (22)

0,010

0,010

Complications, n (%)

23 (13)

9 (14)

14 (13)

1000

0,695

Infections, n (%)

7 (4)

1 (1)

6 (6)

0.245

0.702

Other complications

16 (9)

8 (1)

8 (7)

Inappropriate device therapies, n(%)

7 (4)

7 (10)

0 (0)

0.001

0.730

  1. Continuous variables are normally distributed, expressed as mean and standard deviation. AF: atrial fibrillation; ACEI angiotensine converting enzyme inhibitor; ARB angiotensine receptor blockers; BMI body mass index; BNP brain natriuretic peptide; CABG coronary artery bypass graft; CKD 3b chronic kidney disease stage 3b defined by eGFR< 45 ml/min; CMR-LVEF cardiovascular magnetic resonance left ventricular ejection fraction; COPD chronic obstructive pulmonary disease; eGFR estimated glomerular filtration rate; ICM ischemic cardiomyopathy; LGE Late gadolinium enhancement; MAGGIC meta-analysis global group in chronic heart failure; MRA Mineralocorticoid receptor antagonist; NYHA New-York Heart Association; ppm pulse per minute; PCI percutaneous coronary intervention; SD standard deviation; 2DEcho-LVEF two dimensional echocardiography left ventricular ejection fraction
Back to article page

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us